Agios Pharmaceuticals, Inc.

NASDAQ:AGIO

Biotechnology

Healthcare
$29.68 +1.50%

+$0.50 today

Market cap
$1.78B
Beta
0.59
P/E (TTM)
-4.7
EPS (TTM)
-$7.19
52W Low $22.24High $46.00

Volume 0.60M

Average 1.11M

AGIO Operating Income

Profit from core operations after operating expenses, before interest and taxes.

Agios Pharmaceuticals, Inc.NASDAQ: AGIO

Operating Income · Q1 FY2026 · quarter ended Mar 2026

Operating income remains negative

Q1 FY2026 operating income was -$110.03M, compared with -$106.63M a year earlier. Trailing-twelve-month operating income was -$475.53M.

Context

  • Operating income amounted to 873.9% of revenue in FY2025, down 292.6 pp from a year earlier.
  • Operating income grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether operating income reaches the consensus estimate from 6 analysts of -$330.94M (+29.9%) for the fiscal year ending Dec 2026, a step up from the -10.9% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$110.03M+9.5% QoQ
Last fiscal yearDec 2025
-$472.13M-10.9% YoY
LTMMar 2026
-$475.53M-8.0% YoY
Operating Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-3.2%+22.2%+25.4 pp
1 year-10.9%+29.9%+40.8 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Operating Income history

USD · from the income statement

Latest · FY2025
(472.13M) USD
Year-over-year change
-10.9%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Operating Income vs competitors

How AGIO compares with its peers on the latest reported figures

  • AGIO's LTM Mar 2026 operating income of -$475.53M is the 6th highest of the 7 companies compared; the peer median is -$186.7M.
  • Its year-over-year change of -8.0% is the 2nd highest of 7, against a peer median of -57.2%.
  • Operating income amounts to 720.0% of revenue for AGIO, versus a peer median of 17.4%.
AGIO Competitors Peer median
Operating Income for AGIO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PTCTPTC Therapeutics, Inc.LTM Jun 2026$116.26M -83.8%—11.5%
PHARPharming Group N.V.LTM Mar 2026$23.38M +3514.0%+4.6%6.3%
MIRMMirum Pharmaceuticals, Inc.LTM Jun 2026-$107.66M -88.6%—17.4%
IRONDisc Medicine, Inc.LTM Sep 2026-$265.73M -30.5%——
BCRXBioCryst Pharmaceuticals, Inc.LTM Jun 2026-$313.16M -677.8%—33.3%
AGIOAgios Pharmaceuticals, Inc.LTM Mar 2026-$475.53M -8.0%—720.0%
RAREUltragenyx Pharmaceutical Inc.LTM Mar 2026-$561.78M -9.4%—83.9%
Peer median (excluding AGIO) -$186.7M-57.2%+4.6%17.4%

Competitors are the stored peer set for AGIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue014.24M26.82M36.5M54.03M
Cost of Revenue18.78M1.7M9.5M4.17M11.52M
Gross Profit(18.78M)12.54M17.32M32.33M42.51M
Gross Margin—88.0%64.6%88.6%78.7%
Research & Development256.97M279.91M288.9M301.29M334.36M
Selling, General & Admin121.45M121.67M119.9M156.78M180.28M
Operating Expenses359.64M401.58M408.81M458.07M514.64M
Depreciation & Amortization18.78M8.56M6.62M5.65M5.18M
EBITDA(337.73M)(223.24M)(345.47M)723.62M(408.62M)
EBITDA Margin—-1567.7%-1287.9%1982.6%-756.3%
Operating Income(378.42M)(389.05M)(391.49M)(425.74M)(472.13M)
Operating Margin—-2732.1%-1459.5%-1166.5%-873.9%
Interest Income836K12.79M33.34M48.08M56.38M
Interest Expense00000
Other Income / Expenses21.91M157.25M39.4M1.14B58.34M
Income Before Tax(356.51M)(231.8M)(352.09M)717.97M(413.8M)
Pre-Tax Margin—-1627.8%-1312.6%1967.1%-765.9%
Income Tax Expense00044.24M(1.02M)
Net Income1.6B(231.8M)(352.09M)673.73M(412.78M)
Net Margin—-1627.8%-1312.6%1845.9%-764.0%
EPS (Basic)(6.36)(4.23)(6.33)11.86(7.12)
EPS (Diluted)(6.36)(4.23)(6.33)11.64(7.12)
Weighted Avg Shares60.45M54.79M55.65M56.81M57.97M
Weighted Avg Shares (Diluted)60.45M54.79M55.65M57.89M57.97M

Agios Pharmaceuticals, Inc.

NASDAQ:AGIO

Intrinsic Alpha fair value

Locked

Current Price

$29.68

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.